One company generally characterized as a CRO, but which touts itself as being much more than an outsourcing business, stands out as having actually formed the sorts of risk-sharing arrangements with its pharmaceutical clients that other R&D outsourcers only talk about. AAI is going further than most other CROS are even contemplating: it is willing to accept pre-FDA approval risk in exchange for milestone and royalty rights. AAI is also developing its own compounds, which it will outlicense for marketing.So far, however, the company's recent lackluster financial performance makes it look a lot like other CROs. AAI's management, however, argues that in the long run, its ability to provide product solutions--including the extension of current products through dosage reformulation and drug delivery improvements-- will stand it in good stead by giving pharma companies that are increasingly preoccupied with blockbusters, a way to extend the life of drugs it might otherwise abandon.
You may also be interested in...
Investors in the drug business have had to choose between high-risk, high-reward biotechnology and lower-risk, established pharmaceutical companies with predictable earnings streams. In either case, they take on development risk--the possibility that products will fail in clinical trials and affect the company working on them. But now Paul Capital Partners hopes to capitalize on the largely unexplored niche of investing only in commercial risk. It recently closed its $300 million Royalty Acquisition Fund to effectively buy out streams of royalties from marketed products, paying up-front for a drug's lifetime of royalties.
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.